Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?

Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?

IntroductionMedullary thyroid cancer (MTC) is a rare thyroid tumour whose management in advanced stages is challenging, despite effective therapeutic options having expanded in recent years. Proteasome inhibitors (PrIn) have shown the ability to improve patient outcomes, including survival and quali...

Full description

Bibliographic Details
Main Authors: Giuseppe Fanciulli, Roberta Modica, Anna La Salvia, Erika Maria Grossrubatscher, Tullio Florio, Francesco Ferraù, Alessandro Veresani, Flaminia Russo, Annamaria Colao, Antongiulio Faggiano
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Endocrinology
Subjects:
medullary thyroid carcinoma
proteasome inhibitors
bortezomib
carfilzomib
ixazomib
MG132
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1145926/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1145926/full

Similar Items